Skip to main content
Fig. 2 | Acta Neuropathologica Communications

Fig. 2

From: Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma

Fig. 2

Bevacizumab induces proliferation and CSC/EMT markers in U87 cells. In-vitro challenging of U87 cells with bevacizumab (Avastin; 100 µg/ml) for 2 months enhanced cell proliferation (a) and sCD146 secretion (b), normalized to total cell number, as compared to IgG treated cells. Avastin-challenged U87 cells upregulated CD146, VEGFR2 and integrin subunits αv and β3 gene transcription (c) and their membrane expression, except for CD146 (d). U87 challenging with Avastin potently induced expression of markers related to CSC (e) and EMT (f) at the mRNA level as compared to control IgG treated cells. Average of 5 experiments is shown; **p < 0.01, ***p < 0.001, experimental vs control

Back to article page